Back to top

biotechnology: Archive

Zacks Equity Research

SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims

Casava stock falls as the company agrees to pay a cumulative fine exceeding $40 million to settle misleading claims charges brought against it by the SEC.

ANIPNegative Net Change KRYSNegative Net Change SAVANegative Net Change FULCNegative Net Change

Supriyo Bose

Buy 3 Momentum Anomaly Stocks as Markets Bask in Economic Strength

JWN, UHS and PGR are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.

UHSNegative Net Change JWNNegative Net Change PGRNegative Net Change

Zacks Equity Research

Bayer Submits Application for Label Expansion of Prostate Cancer Drug

BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

REGNNegative Net Change PFENegative Net Change LLYNegative Net Change BAYRYNegative Net Change

Zacks Equity Research

Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment

The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.

BMYPositive Net Change ABBVPositive Net Change KRYSNegative Net Change FULCNegative Net Change

Zacks Equity Research

BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies

Biomea stock rises 9% after the FDA lifts clinical hold on two phase I/II studies evaluating the company's lead candidate, BMF-219, for diabetes.

ANIPNegative Net Change KRYSNegative Net Change FULCNegative Net Change BMEANegative Net Change

Zacks Equity Research

Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More

Biohaven and Zevra are in the spotlight following positive updates on key candidates.

BIIBNegative Net Change VNDAPositive Net Change WVENegative Net Change BHVNNegative Net Change ZVRANegative Net Change

Zacks Equity Research

CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study

Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.

CLDXNegative Net Change ANIPNegative Net Change KRYSNegative Net Change FULCNegative Net Change

Zacks Equity Research

Roche's Lupus Study for Gazyva Meets Primary & Key Secondary Goals

RHHBY announces meeting primary and key secondary goals in the late-stage study of its lymphoma drug, Gazyva/Gazyvaro, for treating active lupus nephritis.

RHHBYNegative Net Change ANIPNegative Net Change KRYSNegative Net Change FULCNegative Net Change

Zacks Equity Research

TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study

2seventy bio and partner BMY decide to stop enrollment in the late-stage study on Abecma due to growth in the newly diagnosed multiple myeloma treatment space.

REGNNegative Net Change BMYPositive Net Change NVONegative Net Change TSVTNegative Net Change

Zacks Equity Research

Incyte Gains 12.7% Year to Date: How Should You Play the Stock?

Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise investors to wait and watch before turning positive.

GSKNegative Net Change NVSNegative Net Change INCYPositive Net Change

Zacks Equity Research

WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study

Wave Life Sciences stock soars 53% on positive interim data from a mid-stage study showing superior efficacy of investigational DMD drug, WVE-N531.

ANIPNegative Net Change WVENegative Net Change KRYSNegative Net Change FULCNegative Net Change

Zacks Equity Research

Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea

A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar.

REGNNegative Net Change RHHBYNegative Net Change AMGNPositive Net Change BAYRYNegative Net Change

Zacks Equity Research

VTYX Stock Rises on Strategic Equity Investment Deal With SNY

Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive rights to VTX3232.

SNYNegative Net Change NVONegative Net Change LLYNegative Net Change VTYXNegative Net Change

Zacks Equity Research

Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion

REGN and SNY get positive CHMP opinion on the label expansion of Dupixent in the EU for eosinophilic esophagitis in children down to 1 year of age.

REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change

Zacks Equity Research

Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU

APLS stock falls as the CHMP confirms its June 2024 negative opinion on the regulatory filing for intravitreal pegcetacoplan to treat GA in the EU.

ILMNNegative Net Change KRYSNegative Net Change APLSNegative Net Change FULCNegative Net Change

Zacks Equity Research

NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study

Novo Nordisk stock falls 5.5% on unsatisfactory safety and efficacy data from a mid-stage study of investigational obesity candidate, monlunabant.

NVONegative Net Change LLYNegative Net Change VKTXPositive Net Change CRBPNegative Net Change

Ahan Chakraborty

NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?

Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.

NVONegative Net Change LLYNegative Net Change AMGNPositive Net Change VKTXPositive Net Change

Zacks Equity Research

Roche Antiviral Drug Reduces Transmission in Late-stage Study

Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected person to household members.

RHHBYNegative Net Change PFENegative Net Change LLYNegative Net Change BAYRYNegative Net Change

Zacks Equity Research

Company News for Sep 20, 2024

Companies In The News Are: PGNY, EWTX, FDS, SCS.

FDSPositive Net Change SCSNegative Net Change PGNYNegative Net Change EWTXPositive Net Change

Zacks Equity Research

EWTX Stock Soars on Upbeat Efficacy Data From Cardiomyopathy Studies

Edgewise stock soars on positive data from an early-stage study and Part A of a mid-stage study of EDG-7500 in obstructive hypertrophic cardiomyopathy patients.

ILMNNegative Net Change KRYSNegative Net Change FULCNegative Net Change EWTXPositive Net Change

Zacks Equity Research

APLT Stock Soars 69% on Positive Update on Galactosemia Drug NDA

Applied Therapeutics stock surges 69% as the FDA says that no advisory committee meeting is required to discuss the govorestat NDA for classic galactosemia.

ILMNNegative Net Change KRYSNegative Net Change APLTNegative Net Change FULCNegative Net Change

Zacks Equity Research

Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates

Gilead Sciences and Nuvalent are in the spotlight following positive updates on key candidates.

REGNNegative Net Change GILDPositive Net Change MRNANegative Net Change ZNTLPositive Net Change NUVLNegative Net Change